Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Equity Average (2020 - 2025)

Caribou Biosciences has reported Equity Average over the past 6 years, most recently at $132.0 million for Q4 2025.

  • Quarterly Equity Average fell 50.57% to $132.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.0 million through Dec 2025, down 50.57% year-over-year, with the annual reading at $187.6 million for FY2025, 39.63% down from the prior year.
  • Equity Average was $132.0 million for Q4 2025 at Caribou Biosciences, down from $154.0 million in the prior quarter.
  • Over five years, Equity Average peaked at $396.1 million in Q4 2021 and troughed at -$41.7 million in Q2 2021.
  • The 5-year median for Equity Average is $292.7 million (2023), against an average of $256.5 million.
  • The largest YoY upside for Equity Average was 2497.89% in 2021 against a maximum downside of 1346.31% in 2021.
  • A 5-year view of Equity Average shows it stood at $396.1 million in 2021, then decreased by 21.11% to $312.5 million in 2022, then rose by 22.67% to $383.3 million in 2023, then tumbled by 30.33% to $267.1 million in 2024, then plummeted by 50.57% to $132.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Equity Average are $132.0 million (Q4 2025), $154.0 million (Q3 2025), and $191.7 million (Q2 2025).